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While management of atrial fibrillation (AF) patients is improved by guideline-conform application of anticoagulant therapy, rate control,
rhythm control, and therapy of accompanying heart disease, the morbidity and mortality associated with AF remain unacceptably high.
This paper describes the proceedings of the 3rd Atrial Fibrillation NETwork (AFNET)/European Heart Rhythm Association (EHRA) con-
sensus conference that convened over 60 scientists and representatives from industry to jointly discuss emerging therapeutic and diagnostic
improvements to achieve better management of AF patients. The paper covers four chapters: (i) risk factors and risk markers for AF;
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(ii) pathophysiological classification of AF; (iii) relevance of monitored AF duration for AF-related outcomes; and (iv) perspectives and needs
for implementing better antithrombotic therapy. Relevant published literature for each section is covered, and suggestions for the improve-
ment of management in each area are put forward. Combined, the propositions formulate a perspective to implement comprehensive man-
agement in AF.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Introduction
Atrial fibrillation (AF) is one of the major common and chronic dis-
orders in modern cardiology. Due to its loss of heart rate control,
diminished atrial contraction, and especially its propensity to
thrombogenesis, AF can cause ischaemic stroke and systemic
thromboembolism, heart failure, impaired quality of life, and fre-
quent prolonged hospitalizations. Furthermore, mortality rates
are doubled in patients with AF, with acute coronary syndromes
and other vascular complications being frequent. Despite recent
advances in AF therapy, including the broader use of anticoagulant
therapy, adequate rate control, and newer, safer techniques to
maintain sinus rhythm, which may prospectively help to prevent
adverse outcomes in AF patients, mortality and morbidity in AF
patients remains unacceptably high.
To discuss and propose the next steps and the perspectives to
improve AF management, the German Atrial Fibrillation Compe-
tence NETwork (AFNET, www.kompetenznetz-vorhofflimmern.
de) and the European Heart Rhythm Association (EHRA, www.
escardio.org/ehra) convened over 60 experts from university and
industry settings for the 3rd AFNET/EHRA consensus conference
on AF (for reference to the 1st and 2nd conference, see Kirchhof
et al.1,2). The conference was held in the European Heart House,
the headquarters of the European Society of Cardiology (ESC) in
Sophia Antipolis from 7 to 9 November 2010, shortly after the
release of the new ESC guidelines on AF.3
The participants of this conference discussed several aspects of
AF management. For this report, these were grouped into four
main sections:
(1) risk factors and risk markers for AF,
(2) pathophysiological classification of AF,
(3) relevance of monitored AF duration for AF-related outcomes,
(4) perspectives and needs for implementing better antithrombo-
tic therapy.
Risk factors and markers for atrial
fibrillation
The past few decades have seen an immense effort to reduce the
population-wide impact of atherosclerosis and cardiovascular
disease, e.g. by the use of statin therapy, control of hypertension,
and attempts to reduce smoking. Despite reduced risk for arterio-
sclerosis and coronary artery disease, the incidence of AF con-
tinues to increase, indicating that the control of traditional risk
factors for cardiovascular disease may not reduce AF to a similar
extent.
Many risk factors contribute to AF—presumably with some
additive or cumulative effects that increase the individual risk of
developing AF, although many interrelated interactions are
likely.4 Arterial hypertension and congestive heart failure, including
heart failure with impaired or preserved left ventricular systolic
function,5– 8 as well as myocardial infarction, valvular heart
disease and diabetes mellitus, all contribute to development of
AF.9 These risk factors are well established and validated for AF,
and as such, identification of these risk factors requires early inter-
vention and appropriate treatment to prevent disease progression.
Preventing these risk factors may also reduce the risk of developing
AF.2,10 On the other hand, there are emerging risk factors for AF
that have received much less attention and may provide additional
leverage to decrease the incidence of AF, which is emerging as the
new epidemic.
What increases the risk for incident atrial
fibrillation?
Table 1 gives a list of risk factors for incident AF. These are split
into ‘established’ and ‘emerging’ risk factors. Among the estab-
lished risk factors, the best validated risk factors that lead to the
development of AF include age, hypertension, diabetes mellitus,
and heart failure.
Age is one of the key risk factors for AF.9,12,59,70,71 Depending on
the type of study, duration of follow-up and age at start of
follow-up, hazard ratios range between 1.1 and 5.9 per decade
of age. Age-related fibrosis,72 intracellular age-related changes, or
accumulation of accompanying disorders that occur with increasing
frequency with older age may explain this association. On the con-
trary, if AF occurs at young age, genetic factors play a major role
(heritable AF, see below).
Another important and well-established factor is hypertension.
Indeed, the higher the blood pressure, the greater the risk of inci-
dent AF.19,23,24 Interestingly, a systolic blood pressure as low as
130 mmHg and a high pulse pressure amplitude may also increase
the risk of AF.23 This may imply that pre-clinical hypertension may
commonly underlie AF, and suggests that tighter blood pressure
control may be prudent in our efforts to prevent AF. On the
other hand, the association between blood pressure and AF may
be J-shaped, as has been proposed for other cardiovascular
events.24 Lower blood pressures were associated with an
increased risk for AF, possibly, in part, due to severe illness like
sepsis or end-stage heart failure.
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Table 1 Factors for incident atrial fibrillation,
progression atrial fibrillationa, and associated events
Validated risk factors, concomitant
cardiovascular conditions
Hazard
ratio
Age
Benjamin et al. M/F per 10 years9 2.1/2.2
Furberg et al. per 7 years11 1.03
Psaty et al.12 1.1
Verdecchia et al. per 10 years13 1.8 PAF
2.9 CAF
DeVos et al.14 1.6a
Schnabel et al.15 2.3
Gami et al.16 2.0
Aviles et al.17 1.4
Marcus et al.18 1.1/1.1
Chamberlain et al.19 2.1–5.9
Male gender
Benjamin et al. M/F per 10 years9 1.5
Furberg et al. per 7 years11 –
Schnabel et al.15 1.9
Gami et al.16 2.7
Gammage et al.20 2.4
Aviles et al.17 1.7
Marcus et al.18 1.6/1.7
Chamberlain et al.19 1.9
Validated risk factors, concomitant
cardiovascular conditions
Hazard
Ratio
Hypertension
Benjamin et al.9 1.5/1.4
Furberg et al.11 1.4
Krahn et al.21 1.4
Psaty et al.12 1.1
DeVos et al.14 1.5a
Schnabel et al.15 1.2
Treated hypertension 1.8
Rosengren et al.22 1.7
Treated hypertension 2.1
Gammage et al.20 1.4
Aviles et al.17 1.3
Conen et al.23
Syst 130–140/140–160/.160 1.4/1.7/2.2
Diast 85–90/90–95/.95 1.3/1.5/1.5
Thomas et al.24 Achieved blood pressure: syst
,120 and.140: J shaped curve 2/2
Marcus et al.18 1.5
2.1
Chamberlain et al.19 1.4/2.2
Valvular heart disease
Benjamin et al.9 1.8/3.4
Furberg et al.11 3.2
Krahn et al.21 3.2
Psaty et al.12 2.2
Heart failure
Benjamin et al.9 4.5/5.9
Furberg et al.11 2.8
Continued
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Table 1 Continued
Validated risk factors, concomitant
cardiovascular conditions
Hazard
ratio
Krahn et al.21 3.4
Schnabel et al.15 3.2
DeVos et al.14 aprogression to permanent AF 2.2a
DeVos et al.14 7.7
Gammage et al.20 3.8
Aviles et al.17 1.4
Tsang et al.8 2.1
Marcus et al.18 3.0/2.9
Chamberlain et al.19 3.0
Diabetes
Benjamin et al.9 1.4/1.6
Furberg et al.11 –
Gammage et al.20 2
Marcus et al.18 1.5
2.1
Chamberlain et al.19 1.9
Coronary artery disease (MI)
Benjamin et al.9 1.4/–
Furberg et al.11 –
Krahn et al.21 3.6
Psaty et al.12 1.4
Gami et al.16 ,65 years 2.7
Tsang et al.8 2.2
Marcus et al.18 2.2
3.6
Schnabel et al.15 1.4
Chamberlain et al.19 2.2
Associated risk factors, genetic conditions Hazard
Ratio
Genetic factors
Family history
Fox et al.25 1.9
Arnar et al.26 1.8
Marcus et al.18 1.2
AF susceptible loci identified by GWAS
Ellinor et al.27 1q25 lone AF 1.1
Gudbjartsson et al.28 4q25 1.5
Benjamin et al.29 1.7
1.3
Less validated risk factors and risk markers Hazard
Ratio
Obesity/BMI
Krahn et al.21 1.3
Tsang et al.30 BMI . 30; .35a 1.5/1.9a
Tedrow et al.31 BMI. 25/.30 1.2/1.7
Frost et al.32 BMI. 30 M/ F 2.3/2.0
Schnabel et al.15 1.2
Rosengren et al.22 BMI. 27.5 1.7
Gami et al.16 only ,65years per 1 kg/m2 1.1
Wang et al.33 BMI. 30 M/F 1.5/1.5
Dublin et al.34 per unit BMI 1.03
Continued
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Table 1 Continued
Less validated risk factors and
risk markers
Hazard
ratio
Marcus et al.18 –
–
Chamberlain et al.19 .25/.30 –/1.8
Watanabe et al.35 1.8
Blood pressure/ pulse pressure
Psatyet al.12 syst BP per 10 1.1
Mitchell et al.36 per 20 mmHg 1.3
Conen et al.23
Syst 130–140/140–160/.160 1.4/1.7/2.2
Diast 85–90/90–95/.95 1.3/1.5/1.5
Height
Psatyet al.12 per centimetre 1.03
Mont et al.37 .1.77 16.5
Rosengren et al.22 .1.8 m 1.7
Chamberlain et al.19 .1.73 1.9
Sleep apnoea syndrome
Stevenson et al.38 2008 3.0
Gami et al.16 only ,65 years 3.3
Gami et al.39 2.2
Subclinical hyperthyroidism
Sawin et al.40 (relative risk) 3.1
Gammage et al.20
Cappola et al.41
Heeringa et al.42 1.9
Alcohol consumption (often excessive)
Conen et al.43 1.5
Rosengren et al.22 1.3
Mukamal et al.44 former 1.3
Kadoma et al.
Chronic kidney disease
Iguchiet al.45
Baber et al.46 1.9
Asselbergs et al.47 albuminuria 1.5
Go et al.48 1.9
Horio et al.49 1.4a
Competitive or athlete-level endurance sports
Mont et al.37 22.8
Abdulla et al.50 meta-an 5.3
Aizer et al.51 5–7 days/week 1.7
Molina et al.52 8.8
Elosua et al.53 2.9
Chronic obstructive pulmonary disease
DeVos et al.14 aprogression to permanent AF 1.5 n.s.
aStroke 2.0
Smoking
Benjamin et al.9 – /–
Furberg et al.11 –
Krahn et al.21 –
Heeringa et al.54 current/former 1.5/1.5
Rosengren et al.22 1.3
Schnabel et al.15 current –
Chamberlain et al.19 current/former –/–
Continued
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Table 1 Continued
Less validated risk factors and
risk markers
Hazard
ratio
Coffee
Mattioli et al.55
Conen et al.56
PR interval
Cheng et al.57 per 20 ms 1.1
Schnabel et al.15 1.2
Cheng et al.57 aall mort .210 ms 1.4
Chamberlain et al.19 . 200 ms 2.7
Murmur
Schnabel et al.15 2.4
Chamberlain et al.19 1.9
Biomarkers haemodynamic stress
ANP
Schnabel et al.58 1.5
Latini, Masson. J Int Med 2010 ANPa1st re AF 1.2
Smith et al.59 1.6
BNP
Schnabel et al.58 1.6
Latini et al.60 BNPa1st re AF 1.2
Smith et al.59 no
Patton et al.61 1st vs. 5th Qu 4.0
Biomarkers of inflammation (C-reactive protein, IL6,
TNF-alfa a.o.)a
Issac et al.62 (review)
Schnabel et al.63 (osteoprotegrin)
Schnabel et al.58 (C-reactive protein) 1.3
Conen et al.64 (multimarker sc. 3) 1.3
Masson et al.65 rec AFa 1.6
Aviles et al.17 C-reactive proteinCHS 1st vs. 4th Q No
Smith et al.59 2010 1.3
Marrott et al.66 1st vs. 5th Qu 1.2
Genetically elev C-reactive protein 2.2
0.9
Newer, less established risk factors or markers Hazard
Ratio
Birth weight
Conen et al.67 .4 kg 1.7
Biomarkers of cardiac damage
Latini et al.60 TNTa 1.2a
Pre-clinical atherosclerosis
Heeringa et al.68 carot int med M/F 1.6/2.1
Furberg et al.11 –
Psaty et al.12 –
Psychological determinants
Mattioli et al.55
Eaker et al.69
aNo longer associated with incident AF after adjustment for left atrial diameter.
– : No significant association.
ARIC: atherosclerosis risk in communities; CAF: chronic atrial fibrillation; CHS:
cardiovascular heath Study; EHS: Euro Heart Survey; F: female; Fram: Framingham
Study; GWAS: genome wide association study; M: male; MI: myocardial infarction;
PAF: paroxysmal atrial fibrillation; PHS: physical health study; Q: quartile; Qu:
quintile; TNT: cardiac troponin T; WHS: women’s health study.
Comprehensive risk reduction in patients with atrial fibrillation 11
by guest on January 16, 2017
D
ow
nloaded from
 
Other factors such as heart failure are less well defined or used in a
broad sense.9,12,59,70,73 Also included are patients with heart failure
and preserved left ventricular function6,8 and patients with coronary
artery disease, the latter mainly when they present with left ventricu-
lar dysfunction.8,15,16,18,19 The underlying pathophysiological link and
the common pathway for hypertension or heart failure to lead to AF
is atrial pressure and/or volume overload as well as diastolic ventri-
cular dysfunction8,9,11,12,33,37,70 which may lead to atrial dilatation,
fibrosis, and electrical remodelling that finally provides the stimulus
and the substrate for the development of AF.
In a similar way, valvular heart disease leads to pressure and/or
volume overload of the atria, especially the left atrium in left-sided
disease, and has been associated with the development of AF.9,12,70
Male gender has often been associated with incident
AF.9,11,15 –18,20,59 Notably, few females have been included in
trials but some data suggest that females are older and suffer
from more concomitant cardiovascular disease when included.74
This contrasts with the consistent observation that female
gender is a risk factor for stroke in patients with established
AF.75,76 These contrasting associations are difficult to explain:
Whether male gender pre-disposes to AF, whether AF is
more often symptomatic and hence earlier diagnosed in males,
or whether males accrue more (possibly less well validated)
risk factors for AF, or whether females are less likely to seek
medical attention when suffering from AF can only be answered
by additional epidemiological data. Despite a higher burden of
risk factors, blacks appear to be at less risk of developing AF.
Metabolic factors such as diabetes mellitus and hyperthyroidism have
been recognized as independent risk factors for AF.8,9,11,18– 20,37,70,77
More recently, the metabolic syndrome has been recognized as a less
well-established risk factor, although this term may also describe the
summation of several risk factors.35 However, even in this setting,
whether some modifying genetic factors account for the genesis of
AF in individual cases, is unknown.
Less well-established risk factors for incident atrial
fibrillation
There is a range of less well-established risk factors that are associ-
ated with incident AF or with AF-related complications such as
stroke, heart failure, or death. Deciphering the functional conse-
quences of genetic changes associated with AF in the popu-
lation78,79 and epigenetic analyses can teach us more about risk
factors for AF.80 Identifying genetic ‘biomarkers’ that promote
the development of subclinical disease might open new pathways
for risk stratification and prevention of AF (see below).
Traditionally, subclinical hyperthyroidism [normal peripheral
thyroid hormone levels but suppressed thyroid stimulating
hormone (TSH)] has been considered as a modifying factor for
the development of AF, but recent data suggest that even in a pre-
subclinical setting (a newly defined term in this context), the inci-
dence of AF is increased, i.e. when TSH remains in the lower level
of normal or T4 increases within the normal range.20,40– 42
Obesity has recently been revisited as a less well-validated risk
factor for the development of AF in population-based
studies15,16,18,19,21,30– 34 (Table 1). High body mass index also
associates with increased left atrial volume.81 One study suggests
that high birth weight already associates with AF in women .45
years of age.67 Increased epicardial fat also has been associated
with increased AF persistence independent of other risk
factors.82,83 Tall stature also increases the risk of developing AF.22,37
Newer markers of increased risk for AF include the sleep apnea
syndrome which appears to be associated with obesity.16 In addition,
chronic obstructive pulmonary disease14 has been associated with pro-
gression of AF to more permanent forms. Chronic kidney disease also
appears to be a valid marker of increased risk for AF.45,48
Environmental factors such as excessive alcohol consump-
tion,22,43,44 possibly also moderate alcohol consumption84 and
smoking9,11,21 are well-established risk markers for AF. Recent
data confirm the deleterious effects of smoking on incident AF in
contemporary cohorts.15,19,22,85 Many of these factors are com-
ponents of the so-called metabolic syndrome, and may share bio-
logical causes and AF-related effects.
While moderate exercise may protect against AF and can clearly
help to reduce metabolic risk factors for AF, high-level endurance
training is associated with an increased risk of AF in athletes,52,86–88
possibly associated with training-related hypertrophy, diastolic dys-
function, atrial dilatation, and fibrosis as has been demonstrated in
trained rats.89
Biomarkers for atrial fibrillation
Analysis of patient serum, assessment of cardiac size and function
by imaging including electrocardiogaphy, and genetic analyses all
provide biomarkers that may be helpful to refine assessment of
AF risk. Although validation in large patient sets is pending, it is
conceivable that serum biomarkers may help to assess AF risk.
Natriuretic peptides are emerging as new serum risk factors. In a
population-based sample of middle-aged people, these biomarkers
had incremental value for the prediction of incident AF.58,64,90– 93
Notably, atrial natriuretic peptide (ANP) might be a better predic-
tor for AF than brain natriuretic peptide (BNP),59 although other
studies have shown the opposite.61 Preliminary data suggest that
higher levels of natriuretic peptides (and of C-reactive protein,
see below) may also increase the risk for stroke in AF patients.
C-reactive protein and interleukin-6
Analysis of myocardial biopsies demonstrates infiltration by inflam-
matory cells in patients with AF.47,62,94 Likewise, (high-sensitivity)
C-reactive protein or interleukin-617,47,59,95,96 is associated with
AF. Overall, the association of serum biomarkers with AF is not
uniformly found.17,65,90
Echocardiographic estimators of left atrial size may provide an
‘integral’ of the degree of left atrial structural changes over time,
and thereby relate to incident AF or to AF-related complications,
including death.97,98 Left atrial size or volume and left ventricular
mass may predict AF, and left atrial volume even relates to
death.13,99,100 In addition, abnormal ventricular relaxation and dias-
tolic dysfunction were predictors of first diagnosed non-valvular
AF among elderly men and women,8 and large size and anatomy
of the atrial appendages may also relate to AF and its
complications.101,102
Detailed imaging of atrial function
Left atrial size and volumes can be assessed routinely with M-mode
echocardiography. 2D echocardiography is more precise, but also
P. Kirchhof et al.12
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more operator-dependent.103 Three-dimensional imaging tech-
niques (echocardiography, computed tomography, and cardiac
magnetic resonance imaging) provide the most accurate infor-
mation on the exact atrial size, shape, and volume.104,105 From
3D echocardiography and cardiac magnetic resonance imaging,106
the total atrial emptying fraction, active atrial emptying fraction
(active contraction), passive atrial emptying fraction (conduit func-
tion), and atrial expansion index (reservoir function) can be
assessed.107,108 Moreover, the left atrial velocities and active defor-
mation (strain) can also be assessed with sophisticated echocardio-
graphy,109 and left atrial synchronicity can also be derived.110,111
Despite the availability of these modalities, there is still a lack of
data showing correlations between such parameters and incident
AF as well as of complications of AF. In addition, whether improve-
ments of these parameters are associated with better outcome
needs to be assessed. Transoesophageal echocardiography may
furthermore provide information on stroke risk beyond traditional
stroke risk factors.112
Visualizing atrial scars and fibrosis
Another important measurement is the detection of left atrial fibro-
sis and scar tissue as assessed by delayed-enhanced magnetic reson-
ance imaging. The technique is relatively sensitive and specific for
transmural radio frequency-induced lesions.113,114 The extent of
scar tissue and fibrosis on 3D delayed-enhanced magnetic resonance
imaging is inversely related to left atrial performance measured by
echocardiographic left atrial strain and strain rate,115 and large
areas of delayed enhancement in the left atrium may predict recur-
rent AF after catheter ablation.113 Hyper-enhancement of the left
atrial wall was observed after ablation, representing scar tissue,
and the extent of scar tissue 3 months after the ablation was
related to freedom of AF after ablation.116 –118 Technicalities of mag-
netic resonance-based imaging of atrial fibrosis and scar render
reproducibility of these findings challenging, and visualization of
scars is likely limited to transmural lesions.
ECG-based parameters
ECG-based parameters such as long (within the normal range) or
prolonged PR interval clearly relate to AF in the population,15,119
possibly related to atrial structural remodelling and delayed
intra-atrial conduction.15,19,57 Similarly, longer P wave duration
also associates with the risk for developing AF.120 – 122
Depressed heart rate variability may pre-dispose survivors of a
myocardial infarction to AF.123 Furthermore, the observation of
an episode of AF after cardiac surgery may identify patients at
high subsequent risk of developing AF. Similar to the serum bio-
markers discussed above, electrocardiogram (ECG) changes may
be proxies or ‘integrators’ of other risk factors, e.g. prolongation
of PR interval may be a sign of sodium channelopathies
(see ‘genetic factors’), but may also reflect damage to atrial
conduction.
Genetic factors
Genetic factors are associated with AF, especially of pre-mature
onset of AF. In a small number of patients (5% of AF patients,
more in patients with early onset-AF), mutations associated with
genetically conferred cardiomyopathies can be identified such as
long QT syndrome,124 –129 Brugada syndrome,130 short QT syn-
drome,128,131 atrial septal defects,132 or hypertophic cardiomyopa-
thy.133 –135 Some of these patients carry a familial predisposition to
AF (25,26,131,136; see overview in Kirchhof et al.2). On the popu-
lation level, several single nucleotide polymorphisms (SNPs)
close to the PITX2 gene located on chromosome 4q25 strongly
associate with AF,28,137 especially with early-onset AF.138 Other,
weaker associations are found on chromosome 1q2527 and on
chromosome 16.29 Association of other polymorphisms with AF,
found in smaller cohorts, could often not be replicated, indicating
the risk of overreporting of ‘false positive’ results.139 The molecu-
lar mechanisms conferring AF in such a setting have recently been
investigated in genetically modified models for long QT syn-
drome140 and in models with reduced PITX2 expression.78,79
Open questions
Distinction between risk factors and risk markers
AF risk factors are clinically measurable indicators of a biological
process that relates to AF, while risk markers are proxies to an
AF-causing process, but do not contribute by themselves to the
biology of AF. A clear separation between risk markers and risk
factors is not always possible since not all biological causes of AF
are well understood (Table 1). Moreover, it is not well under-
stood how these risk factors and risk markers interact, i.e. aggra-
vate or mask each other, and whether there are special
subgroups where risk factors have a different meaning. Future
research will hopefully give us more insight into risk factors
and markers that predispose to AF and its associated
complications.
Role of biomarkers
With the notable exception of the Framingham cohort study and
population-wide genomic analyses, most reports on serum,
imaging-based, or genetic biomarkers have been done in small
patient cohorts and require validation in other patient series that
allow sufficient control of confounding factors.18,25,26,141 Some of
the large antithrombotic trials may provide opportunities to
relate AF recurrences and other outcomes to biomarkers.
Are there specific factors for progression of AF?
The vast majority of patients experience AF as a chronically pro-
gressive disease that will eventually end up in permanent AF.1,142
The available data suggest that these factors overlap largely with
factors that lead to the development of AF (see above). In the
German Atrial Fibrillation Network (AFNET) registry, the more
of these factors were present, the greater the likelihood that
patients had persistent or even permanent AF.143 Likewise, the
EuroHeartSurvey investigators recently proposed the ‘HATCH’
score (based on risk factors for AF progression—Heart failure,
age, previous transient ischaemic attack or stroke, chronic obstruc-
tive pulmonary disease, and hypertension) which identifies patients
who will progress from paroxysmal to persistent AF.14 There is a
clear and unmet need to identify and characterize factors associ-
ated with progression of AF, and the relative contribution of estab-
lished risk factors for progression, first occurrence, or first
recurrence of AF.
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In summary, many of the classical clinical parameters used to
assess stroke risk are also risk factors for the development of
AF. The impact of each risk factor may vary by age: genetic
factors, obesity, and endurance sports may be more likely to
predict AF in younger patients, while other factors may be more
prevalent and relevant in older AF patients. Disease severity (e.g.
blood pressure value in hypertension, actual left ventricular func-
tion, among others) will be relevant for risk assessment. Many
factors are interrelated and their interaction may enhance or
even annihilate the impact of the new marker with respect to
established markers. The available data on ‘new’ risk factors are
often derived from observational studies with technical limitations.
Furthermore, there is a complex interaction between risk factors
and ‘disease severity’. Several of the newly proposed markers
may reflect disease severity, while others such as left atrial size
may integrate the total atrial damage. Almost all currently available
data sets are based on detection of AF by a simple, short ECG.
This does not take into account that risk factors may contribute
to perpetuation of AF, also neglects ‘silent’ AF which may be diag-
nosed by intensified ECG monitoring (see below) and may impact
the relevance of several risk factors.1,144,145 There is a clear need
to investigate and quantitate the impact of the known risk
factors on ‘early AF’ and silent AF and to better characterize
their interrelation.
A pathophysiologically oriented
classification of atrial fibrillation
to guide therapy
Currently, AF is classified by duration (paroxysmal, persistent,
long-standing persistent, permanent)3,146 and by the extent of
AF-causing symptoms (EHRA score I– IV, or CCS-SAF score 0–
IV).3,147 The symptom classification reflects the need for thera-
peutic interventions, especially rhythm control therapy. In part,
the duration of AF gives a simple reflection of the extent of
‘atrial structural damage’, but this is a very indirect assessment at
best. A classification of AF types based on the underlying patho-
physiology, in contrast, could help to better select therapies for
specific AF patients based on the type of underlying cause and/
or the degree of atrial damage. Thereby, the guideline-supported
recommendation to treat underlying conditions would be substan-
tiated.3,146 Therefore, to better guide therapy, the group proposes
a classification of AF types based on the presumed AF-causing
mechanisms, the validity of which requires further clinical studies
(Table 2).
Inherited atrial fibrillation
This type of AF is best characterized by AF with familial clustering,
often of early onset. Early onset has been defined by a diagnosis of
AF before the age of 65 years.138
Monogenic forms
Atrial fibrillation is a common finding in patients with inherited,
monogenic cardiomyopathies, and other, infrequent familial
forms of AF occur without other signs of heart disease.131,136
Monogenic forms of AF appear to underlie the arrhythmia in
5% of AF patients.2,3,148 It is conceivable that specific therapy
of the underlying cardiomyopathy, including specific antiarrhythmic
drugs in patients with ‘electrical cardiomyopathies’, may help to
prevent AF in these patients. In families with early-onset AF in
the absence of known cardiomyopathies, it may be worth studying
the subtle ECG abnormalities such as a slightly prolonged or shor-
tened QT interval, QRS amplitudes within the upper range of
normal, or slight changes of the right pre-cordial ST segments.
Polygenic forms
A family history of AF is one of the risk factors for incident AF,
outside of clear familial clustering (Table 1). In the past years,
several population- and genome-wide association studies have
identified small genetic changes [single nucleotide polymorphisms
(SNPs)] that are associated with AF. The strongest association
with AF and stroke is found on chromosome 4q25,28,138 close to
the PITX2 gene (see above). Deletion of pitx2 has recently been
implicated in AF genesis in transgenic models.78,79 In addition to
these genetic factors, epigenetic modifiers and other modifiers of
concomitant conditions may also contribute to ‘polygenic’ AF.
There is an overlap between polygenic forms of AF and complex
AF. At present, there is no specific therapy for polygenic AF
forms, but understanding the pathophysiology associated with
these genetic abnormalities may help to develop such therapies
in the future.
Focal atrial fibrillation
In the absence of severe cardiac disease, the initial event that
conveys AF is often atrial ectopy from the pulmonary veins.149
Many short episodes of AF are a good clinical indicator for this
pathophysiology. There is a continuum from atrial ectopy, atrial
‘runs’, and short lasting atrial tachycardias to self-terminating AF.
It is worth emphasizing that this type of AF should be differentiated
from other (longer-lasting) forms of AF. Atrial fibrillation due to
one or a few re-entrant drivers will also present with very
similar electrical and clinical characteristics.150 – 152 Long-lasting
focal AF may lead to multiple wavelet complex AF.
Complex atrial fibrillation
This form of AF identifies the ‘typical’ AF patient, often at
advanced age, who is suffering from concomitant cardiovascular
diseases (e.g. those listed in Table 1), and who usually has pre-
existing left atrial damage and/or enlargement. ‘Complex AF’ is
a consequence of several pathophysiological processes, including
(but not limited to) AF-induced electrical remodelling, structural
changes in the atria, pressure and volume overload secondary
to external conditions such as ventricular cardiac dysfunction or
arterial hypertension, subtle genetic pre-disposition, and age.148
Within this group of patients, the degree of ‘complexity’ is
highly variable between patients. The most direct description of
the complexity of AF stems from assessment of the number of
fibrillation waves by direct contact mapping.153 –156 Patients with
persistent AF harbour a several fold higher number of fibrillation
waves than patients with acute AF. Also, non-invasive assessment
of the AF substrate using ECG-based imaging has recently shown
large variability in complexity of AF.157 It is worthwhile to study
whether non-invasive assessment of the AF substrate is capable
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to resolve the AF substrate complexity in clinically meaningful
ranges.158 – 160
In animal studies, the number of fibrillation waves increased
with both shortening of refractoriness as well as accumulation
of collagen in the extracellular matrix161,162 resulting in increasing
electrical dissociation within the epicardial layer163 and between
the epicardial layer and the endocardial bundle network.164 In
these studies, the number of fibrillation waves inversely correlated
with the ability of antiarrhythmic drugs to cardiovert AF,
suggesting that complexity might serve as a relevant predictor
for successful rhythm control. It appears reasonable to assume
that less complex forms of AF respond better to rhythm
control therapy, but this has not been tested yet. In cases with
a higher degree of complexity, more extended ablation pro-
cedures might be required and antiarrhythmic drugs might be
less effective. Such a graded therapy2 might help to identify the
best treatment option for an individual patient, to enhance the
success rate of pharmacological cardioversion or catheter ablation
therapy, to avoid unnecessary complications due to inadequate
rhythm control therapy, and finally to reduce AF-related health
care costs. In cases of very high substrate complexity, one may
refrain from any attempt of rhythm control therapy. This
concept requires testing in controlled clinical trials, e.g. by asses-
sing AF complexity at baseline.
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Table 2 Atrial Fibrillation Competence NETwork/European Heart Rhythm Association classification of atrial
fibrillation by aetiology and suggested ‘type-specific’ therapy
AF type Pathophysiological mechanism Diagnostic characteristics Proposed ‘specific’ therapy
Inheritable AF Patients with AF and inheritable
cardiomyopathies (short QT, Brugada,
LQTS, or hypertrophic cardiomyopathy,
among others)
Gene-defect-related ECG-abnormalities,
echo-diagnosis of inherited
cardiomyopathy, family history, genetic
testing
Therapy of underyling cardiomyopathy.
Pharmacological reversal of the
genetic defect (possibly, but not
necessarily targeting the ion channel
carrying the gene defect)
A: Monogenic
Inheritable AF Currently under study. Manifestation as AF
at young age (,65 years) with or
without familial clustering
AF of early onset, often with some familial
aggregation of AF, no evident specific
underlying cardiovascular disease causing
the arrhythmia
Not yet identified
B: Polygenic
Focal AF Localised triggers, in most cases originating
from the pulmonary vein(s)
Pattern of frequent, but short-lasting episodes
of AF with distinguishable P waves (coarse
AF), atrial ectopy, and/or atrial tachycardia
deteriorating in AF. AF mainly due to one
or a few re-entrant drivers is also
considered to be part of this type of AF
Isolation of the pulmonary vein(s),
extended/repeated ablation
procedures might be required
Complex AF AF that is maintained by functional multiple
reentrant wavelets. Complex AF is
common and promoted by shortening
of atrial refractoriness (e.g.
tachycardia-induced atrial remodelling
or enhanced parasympathetic tone) or
localised conduction disturbances due
to atrial fibrosis induced by structural
heart disease
Long-lasting episodes, or persistent AF with
non-distinguishable P waves (fine AF)
Therapy depending on grading of the
substrate complexity:
low complexity: AADs or PVI
The following therapeutic measures aim at
quantification of the degree of substrate
complexity:
Moderate complexity: AADs and/or
extended/repeated ablation
procedures
Frequency and ampltitude of P waves
(primarily reflecting right atrial
electrophysiological properties).
High complexity: rate control (AAD and
ablation ineffective)
Frequency and amplitude of local wall
movements recorded by tissue velocity
imaging (electroechocardiography)
In these patients, both primary
prevention of AF in patients with
structural heart disease, and possibly
also secondary prevention of AF by
upstream therapy should be
considered (unless contra-indicated)
Complex AF is also the ‘final common
pathway’
Incidence of complex fractionated atrial
electrograms (CFAE).
Non-invasive imaging:
Atrial enlargement, scarring, and potentially
atrial fibrosis as reflected by MRI
Post-operative
AF
AF after cardiac surgery, multifactorial
aetiology
Transient AF in post-operative setting Prevention by beta-blockers, steroids,
antioxidants. Treatment should
consider both the transient nature of
post-operative AF and the fact that
post-operative AF may indicate an
increased likelihood of recurrent AF
in the future
Acute factors: Inflammation, surgical
trauma, high sympathetic tone,
electrolyte changes, volume overload
Chronic pre-disposition: Genetic factors,
atrial structural remodelling due to
structural heart disease
The group acknowledges that ‘complex AF’ comprises a relatively inhomogeneous group of patients, and that further classification of this type of AF may be required to guide
management better.
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Post-operative atrial fibrillation
Post-operative AF is an intriguing subform of AF. One in five to one
in three patients undergoing cardiac surgery suffer from post-
operative AF. Many transient factors contribute to the occurrence
of post-operative AF. Such patients undergo severe changes in
fluid, electrolyte, and haemodynamic status, suffer from a systemic
inflammatory reaction, enhanced sympathetic tone,93,165– 168 and
surgical trauma to the atria.169 Manifestation of AF post-surgery
may also indicate the existence of a pre-disposing substrate poss-
ibly due to the underlying structural heart disease,155 and hence AF
often recurs months to years after an episode of post-operative
AF. As enhanced sympathetic tone and inflammation are the
most relevant factors pre-disposing to post-operative AF, beta-
blockers and anti-inflammatory compounds can be effective in its
prevention. In any case, the transient nature of AF has to be con-
sidered in the decision making process (e.g. transient use of anti-
arrhythmic drugs or anticoagulation therapy).
‘Silent’ atrial fibrillation and the
significance of atrial fibrillation
detected by long-term
monitoring devices
Atrial fibrillation is a chronically progressive disease1,170 that will
eventually be picked up by palpating the pulse, followed by an
ECG to establish diagnosis.3 Indeed, prolonged monitoring,
usually by prolonged Holter ECG recordings for 7 days, may
detect AF in 1 in 20 or even 1 in 10 patients admitted with
acute stroke and being in sinus rhythm at the time of admis-
sion.171 – 173 Unfortunately, many patients with AF are only diag-
nosed after the first complication of the arrhythmia, often an
ischaemic stroke, substantiating the need for early detection and
therapy of AF.2,3,10,174 Recent advances in long-term ECG moni-
toring such as prolonged use of Holter ECG devices for up to
30 days or telemetric ECG surveillance in hospitals have already
extended the possibilities of detecting ‘silent’ AF. The need for
more accurate and extended diagnostic periods may also be
met by implanted devices which could theoretically provide con-
tinuous information on atrial rhythm, or by long-term external
recording devices.170,175,176
Whether short atrial high-rate episodes (AHRE) recorded by
an implanted device from an intracardiac lead have the same
clinical implications and prognostic impact in patients without
ECG-documented AF as AF documented by ECG is not clear.
This open questions has two aspects: (i) the need for more
data on the validity and reliability of implanted subcutaneous
monitors to detect ‘true’ AF and (ii) the clinical need to demon-
strate that such ‘silent’ AF episodes have the same prognostic
impact as AF detected by conventional methods. These open
questions notwithstanding, the available data suggest that these
patients are at increased risk for stroke and also put forward
the concept that patients who spend more time in AF are at
higher risk for complications than patients who spend less
time in AF.144,145,175,177 –179
The conundrum of atrial fibrillation
burden
The term ‘AF burden’ has been proposed as the total amount of
time spent in AF per monitored time period. It should be con-
sidered that AF burden represents a heterogeneous entity; for
example, many short episodes of AHRE could result in the same
AF burden as a single long-standing episode, and may have different
biological effect on atrial electrical and contractile function, and on
remodelling and coagulation processes.
Mainly driven by the technical accuracy of AF detection, a dur-
ation of .5–6 min has been associated with stroke and
death.145,175,177 Other analyses also suggest that longer times
spent in AF are associated with slightly higher stroke risk, and
that this increased risk is independent of classical stroke risk
factors.175,177,178,180 There is a clear need to unify the definitions
of AHRE across device manufacturers, and to investigate the
impact of short AHRE episodes (,5 min duration) on outcomes
and stroke risk estimation. It may be speculated that prevention
of AF could help to reduce residual strokes in patients with AF
on anticoagulant therapy.174,181 This will be tested in the EAST
(Early Treatment of Atrial Fibrillation for Stroke Prevention
Trial) trial (ISRCTN04708680).
Implantable subcutaneous devices can provide continuous
cardiac rhythm monitoring in patients that do not require pace-
makers or defibrillators.182 The diagnostic accuracy of subcu-
taneous ECG monitors is good, but implanted monitors may
not detect all episodes of AF picked up by conventional, manually
analysed Holter ECG.183 For a balanced approach to patients
with AHRE detected by implanted devices, the group proposes
a stepwise procedure to document AHRE (Figure 1). To establish
the diagnosis from intracardiac recordings or implanted devices,
criteria may differ from established criteria to diagnose AF in
the surface ECG.3 A uniform (company-independent) standard
for the definition of AHRE by subcutaneous and intracardiac
devices is clearly needed for the clinical evaluation and implemen-
tation of detecting silent AF by such devices.
Improving stroke prevention
by antithrombotic therapy
Oral anticoagulation clearly prevents ischaemic strokes in AF
patients3 and most patients with AF are likely to benefit from antic-
oagulant therapy.3,184– 186 In general, AF patients at risk of stroke
can be identified by validated stroke risk factors, and recent guide-
lines reflect a paradigm shift in recommending an approach in
which anticoagulation is a default antithrombotic therapy in AF
patients.3,146,184,187 But this effective and potentially life-saving
therapy comes at the price of inducing relatively infrequent but
potentially severe bleeding events. Numerically, events that are
counted as major bleeds in large trials occur in similar frequency
compared to ischaemic strokes. In some of the recent trials, bleed-
ing events even outnumber strokes. The majority of these bleeding
events, however, have less clinical impact than ischaemic strokes:
major bleeding events include clinically relevant and less significant
events ranging from the rare but severe intracranial haemorrhage
to less relevant smaller gastrointestinal bleeds.184,186 –189
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However, it is important to remember that ischaemic strokes that
can be prevented by anticoagulant therapy outnumber intracereb-
ral haemorrhages in most AF patients.189 –191
Furthermore, the likely introduction of newer, potentially safer
antithrombotic agents into clinical practice may influence decisions
for anticoagulant therapy, at least according to decision models.192
Detecting an increased risk for
intracranial bleeds
The available data suggest that patients—in contrast to their
treating physicians—are often willing to accept excess bleeds if
this helps to prevent ischaemic strokes.193 Nonetheless,
challenges remain in stroke risk assessment, especially in patients
at increased risk for bleeding. Unfortunately for the decision
models, most bleeding risk factors overlap with stroke risk
factors.194– 196 Nonetheless, variable international normalized
ratio (INR) values, excess consumption of alcohol or drugs, enzy-
matically detected liver damage and renal dysfunction,194,195
incontinence and gait apraxia, as well as certain genetic
factors197 and potentially subclinical lesions (detectable as
amyloid angiopathy) on cerebral magnetic resonance
imaging198 – 202 may identify patients at high bleeding risk. Further-
more, bleeding events accumulate in the first year after initiation
of vitamin K antagonist therapy.203
AF known?
Continue AF 
management
Yes No
Verify presence of AF to establish diagnosis
AHRE detected by an implanted device
Attempt to document AF by
resting and Holter ECG 
monitoring
Review electrograms of 
device during episodes
Consider patient characteristics and 
possibly AHRE duration as the basis 
for management,  such as institution of 
antithrombotic therapy. The threshold 
to institute therapy may be lower in 
patients at high stroke risk than in 
patients at lower risk for stroke.
AF documented?
Yes No
Initiate AF management 
including antithrombotic 
therapy.
Consider review of AHRE to relate
 symptoms to AHRE and to adapt rate and
rhytrhm  control therapy  
Figure 1 Approach to patients with atrial high-rate episodes detected by implanted devices. AHRE, atrial high rate episode.
Figure 2 Cerebral computed tomograms of four types of intracranial bleeding (true intracerebral haemorrhage, subdural haematoma, sub-
arachnoidal haematoma, epidural haematoma).
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Whether consideration of such clinical or imaging signals can
help to avoid anticoagulant-induced severe bleeds remains to be
assessed.
Careful classification of intracranial
bleeds
Intracranial bleeds are usually investigated by cerebral imaging
(computed tomography and/or magnetic resonance imaging). For
the acute management of such events as well as for the interpret-
ation in light of anticoagulant therapy, a careful classification of
intracranial bleeds is important. This requires differentiation
between parenchymal brain haemorrhage, epidural or subdural
haematoma, and subarachnoidal haemorrhage (Figure 2). Haemor-
rhagic transformation of cerebral ischaemia is not considered as a
primary bleeding complication. Combination therapy with acetylsa-
licylic acid is a major risk factor for intracranial haemorrhage in
anticoagulated patients.204,205 Intracranial haemorrhages appear
to be less prevalent with dabigatran and also to some extent
with rivaroxaban as compared to warfarin.187,190 The reasons for
this outcome remain speculative, and potential explanations may
include that dabigatran and rivaroxaban do not cross the blood–
brain barrier, at least not in pre-clinical studies,206 or the fact
that dabigatran or rivaroxaban do not interfere with the formation
of TF-VIIa complexes, thereby preserving local haemostatic
mechanims.
Information needed for the clinical use
of newer anticoagulants
Strokes in AF patients not receiving anticoagulant therapy confer a
30-day mortality of 24%.207 Vitamin K antagonists are widely used
throughout Europe and the USA, but their effectiveness is limited
by their narrow therapeutic range, drug–food, and drug–drug
interactions, and the difficulty to maintain patients in the thera-
peutic range. This limits utilization of vitamin K antagon-
ists.143,208,209 There is extensive knowledge about vitamin K
antagonists in the medical community and anticoagulated patients
are familiar with the oral anticoagulation regimen. This knowledge
and experience is lacking at present for the newer anticoagulants.
Therefore, there is a need to educate physicians, including general
physicians,209 and patients about these new compounds, ideally
before they are used (Table 3).
Physicians will need thorough and balanced information on
the therapeutic principles, drug effects, and side effects, manage-
ment of (bleeding) complications, and appropriate action in the
case of overdose. Such information can be communicated with
credibility by independent bodies, e.g. professional and patient
organizations. Furthermore, physicians will need timely and com-
prehensive information on drug–drug interactions for each of
the new compounds, including interactions with over the
counter-medications and drugs that given transiently for other
indications (e.g. antibiotics).
Important information on new
anticoagulants in comparison to
vitamin K antagonists for physicians.
This information should be provided by
the drug manufacturer
Information on AF and concomitant comorbidities.
Characteristics of the novel anticoagulant (trial data,
pharmacokinetics,drug interactions, specialprecautions):
† shorter half-life requires attention to adherence;
† shorter half-life may make periprocedural issues easier, but
this has not been formally tested. Attention to haemostasis
may help to decide on the time point of operations. For
vitamin K antagonists, there are good data for many pro-
cedures that continuation of vitamin K antagonist (with
keeping the INR in the lower therapeutic range) is better
than bridging. When to restart?;
† drug–drug interactions including cytochrome p450
isoenzymes;210
† antagonising the drug in emergencies;
† metabolism and interaction with renal and/or hepatic dys-
function.
Patient preference threshold for stroke and excess
bleeding.
Awareness of patient’s knowledge and understanding
of antithrombotic therapy.
Importance of maintaining drug use.
Monitor renal function in selected patients (recent illness/
renal dysfunction).
What to do in special situations (surgery, acute coronary
syndromes/stents, accidents).
In patients requiring antiplatelet therapy (specifically dual antiplate-
let therapy, e.g. after stenting or acute coronary syndrome), there
is no published trial experience available, and guidance is depen-
dent upon case series and cohort data.211,212 The data on combin-
ing acetylsalicylic acid with dabigatran (40% of patients in RELY
received aspirin at baseline187) also show that a combination of
antiplatelet therapy and anticoagulation is associated with more
bleeding, with no appreciable impact on efficacy outcomes.213
Recent data suggest that ‘triple therapy’214 may be relatively safe
with dabigatran, but the experience even in the large RELY trial
is limited.215 Therefore, we suggest to follow the recommendation
for combination of antiplatelets and vitamin K antagonists in
current guidelines.3,212
Monitoring of anticoagulation with the newer anticoagulants will
only be needed in special situations (e.g. a patient suffering a stroke
on one of the newer substances or emergency). Direct thrombin
inhibitors and factor Xa inhibitors will have an effect on activated
partial thromboplastin time (aPTT), while conventional assessment
of factor Xa activation will not suffice to detect the anticoagulant
effect of these substances. Factor Xa antagonists have a dose-
dependent effect on prothrombin time (PT), with a close corre-
lation to plasma concentrations if neoplastin is used for the
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assay. The readout needs to be in seconds as the INR normaliza-
tion is only validated for vitamin K antagonists. Dabigatran will
increase ecarin clotting time which may be used to monitor the
anticoagulant effect.216 Although the new antithrombotics affect
aPTT, and a marked elevation of aPTT may relate to bleeding
risk, such measures should probably not affect drug dose. Specific
calibrators and controls are currently under development for com-
mercialization, or have recently been made available for clinical
use. Although repeated blood testing to measure anticoagulant
effect has disadvantages, the requirement for repeated blood
testing may increase therapy adherence, and adherence may
decrease when newer drugs that do not require frequent monitor-
ing are used. Providing anticoagulant therapy without the need for
INR monitoring may, on the other hand, free health care resources
for a more comprehensive management approach to AF patients.
Renal dysfunction—a risk marker for stroke
in a complicated situation
A small but challenging group of patients that is increasing are
those with severe renal dysfunction [glomerular filtration rate
(GFR), 30 mL/min]. These patients are at high risk for stroke
and bleeds,48 and it is likely that renal function will deteriorate
over time in most patients with renal dysfunction. It is unlikely
that renal dysfunction—unlike other risk factors—would favour
bleeds in excess of ischaemic events, but it is difficult to validate
as this would require large cohorts with repetitive assessment of
renal dysfunction over time, to assess time trends. Hence, it
appears reasonable to consider severe renal dysfunction as an
additional risk factor for stroke. These patients have been excluded
from antithrombotic trials in AF, and they are also at high risk of
death, myocardial infarction, cardiovascular events, and bleeding.
Based on pharmacokinetic data, the Food and Drug Administration
(FDA) approved the use of a lower dose of one of the newer antic-
oagulants (dabigatran, 75 mg bid) in patients with severe renal dys-
function (GFR 15–30 mL/min), rather than any prospective data
from randomised controlled trials per se. Of note, patients who
entered the trial had a creatinine clearance of 30 mL/min or
more.187 In the typical elderly AF patient with renal dysfunction,
renal function can deteriorate over time, and may be associated
with increase in bleeding events. This is reminiscent of the high
bleeding rate in stroke patients receiving intravenous thromboly-
sis.217 Even experience with vitamin K antagonists in those with
renal dysfunction is limited at present,218 and therefore the
choice of oral antithrombotic agents cannot be based on con-
trolled data. The newer anticoagulants have so far only very
rarely been evaluated in dialysis patients, and some can be
removed by dialysis.216,219
Patient values and preferences in atrial fibrillation
management
Patients need information on AF, but the degree and type of infor-
mation demanded differs between patients. Improvement in AF
patient education appears necessary given the comparatively
higher willingness of valve patients to receive oral anticoagulants
compared to AF patients.193 Public campaigns to palpate your
pulse, followed by ECG screening, may be suitable ways to com-
municate to the general public about AF and its associated risk
to relevant populations, e.g. the elderly, or diabetics. Integration
of such activities into information programmes is helpful.
The home pages of the Atrial Fibrillation Association (UK www.
afa.co.uk), the Stop AF campaign (www.StopAF.org), Anticoagula-
tion Europe (www.anticoagulationeurope.org), the Stroke Associ-
ation (www.stroke.org.uk), and AFNET (Germany, www.
kompetenznetz-vorhofflimmern.de) may provide examples for
providing information to AF patients, with links to country-specific
information. The advent and commercialization of new anticoagu-
lants generates a need to inform and educate patients better. This
is an opportunity for health-care professionals and health-care pro-
viders alike to better inform patients about AF and the risk for
stroke. Seizing this opportunity could help to achieve earlier and
comprehensive management of AF patients.2 In addition to this
general need for information on AF and its complications, there
is also a specific need for information on the new anticoagulants,
which will differ for patients naive to or experienced with
vitamin K antagonists. Dedicated AF clinics may be an opportunity
to close information gaps for patients.
Questions and answers for patient
education on the use of anticoagulants
How do clots form?
What are the different options to prevent clots?
What are the benefits of anticoagulation (in general)?
What are the benefits of the drug that I shall receive?
What are the side effects, in particular, how high is
my risk for bleeding during anticoagulant therapy?
Are thereother therapeutic options, e.g. other drugs?
Does the drug interact with food or other drugs (e.g.
over the counter NSAIDs)?
What happens when I do not take the drug for a day,
for a week, for a month (compliance, adherence)?
How do I take the medication?
† When?
† Before/during/after food (intake of intact capsule in case of
dabigatran)?
† Can I take the drug with other medication?
† What to do in case of a missed dose?
† Explain why the novel anticoagulants do not need monitoring
(particularly for vitamin K antagonist-experienced patients).
Keep a list of all drugs that you take with you.
Information on lifestyle changes (contact sports, use of an
electric razor, pilot’s licence).
What to do in case of overdose and in case of bleeding
(stop medication, local haemostasis, haemodialysis).
The group recommends collaboration between pharmaceutical
and medical device companies, ideally co-ordinated by professional
and scientific organizations, to establish and produce generic
patient education materials. Such a collaboration could end up in
a toolkit for physicians that will help to educate patients, but
also (e.g. internet-based) industry-independent information to
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patients. Patient groups will be helpful in the dissemination of this
information, especially when they are independent of industry.
Information for payers
In addition to the medical and general need for information, insti-
tutions and decision makers will need information on the cost of
new anticoagulants. Such information will need to account for
the local practice of anticoagulant therapy and the local potential
for delivery of the new therapies. Cost estimates should include
cost of the drug, direct and indirect cost of oral anticoagulant
therapy, safety profile, and ideally result in a cost–benefit analysis
over vitamin K antagonists in different European countries. There is
also a clear need to generate data on the external validity of trial
results during clinical use. The use of the new drugs will require
careful analyses of the benefits of the drugs with respect to
‘global’ cost reduction.220 The group recognizes that the pricing
of new drugs and the reimbursement frames set up by payers
will markedly influence the use of the new drugs, and that all cur-
rently available cost-effectiveness estimates are based on assump-
tions as well as on data.
Interventional stroke prevention in atrial fibrillation
patients?
In patients deemed unsuitable for vitamin K antagonist therapy,
often on the basis of bleeding risk, transcatheter closure of the
left atrial appendage has been evaluated as an alternative for
stroke prevention in AF.221 Another possibility is offered by an epi-
cardial suture device that can occlude the left atrial appendage
during concomitant open heart surgery. While technically feasible
and approved in some countries, this intervention will need to be
re-evaluated compared to newer, potentially safer anticoagulants in
patients who are considered unsuitable for vitamin K antagonist
therapy221: Some of those patients will be eligible for newer antic-
oagulants, but patients who have suffered from an unexplained
intracranial haemorrhage on oral anticoagulation, those who are
unlikely to comply with anticoagulation, patients with clear and
absolute contraindications for anticoagulant therapy, or patients
who have suffered an ischaemic stroke on anticoagulant therapy,
may still remain candidates for a left atrial appendage occluder.
The group suggests a trial of such a device in patients with estab-
lished contraindications to oral anticoagulation, possibly involving
one of the newer anticoagulants as comparator therapy.
Stroke prevention beyond anticoagulant therapy
Continuous oral anticoagulation is the cornerstone of stroke pre-
venting in AF patients, and relies on adequate delivery of anticoa-
gulant therapy as evidenced by e.g. achieving therapeutic INR
values.207,222 But even on optimal anticoagulant therapy in con-
trolled trials, the residual stroke rate in AF patients remains unac-
ceptably high at 1.5% per year.184,186,187,223,224
Almost all available studies so far have investigated the effect of
anticoagulant therapy in patients with established AF, often long-
lasting AF. The long-term impact of ‘transient’ AF (e.g. post-
operative AF) and of ‘silent’ AF2,3 is much less well studied,
although even short episodes of AF detected by devices relate
to a stroke risk (see above). Based on this information, it
appears unlikely that rhythm control therapy alone can be suffi-
cient to prevent AF-related strokes. Nonetheless, there is a
signal of reduced stroke rates by dronedarone in the ATHENA
trial.185 Whether this effect was related to preventing AF is not
clear. There are two surveys after ablation of AF (n ¼ 750 and
3300 patients) that detected low stroke event rates in patients
who discontinued anticoagulation.225 The authors of those
studies propose that stopping anticoagulation may be acceptable,
but the stroke risk in these populations and follow-up times was
not sufficient to accrue adequate stroke numbers, especially
when considering the reports on very late recurrences of AF
after ablation.226,227
Hence, rhythm control does not appear to suffice to prevent
strokes in AF in the absence of oral anticoagulation. On the
other hand, rhythm control therapy could well contribute to
reduce residual stroke rates in patients on anticoagulation. It is
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Patient groups likely to benefit (upper part) or
not to benefit (lower part) from therapy with new
anticoagulants, including a switch from existing therapy
with vitamin K antagonists to one of the newer
substances
Patients who are likely to benefit from new anticoagulants
Patients with poor TTR (time in therapeutic range) and INR control
due to
innate/genetics for warfarin metabolism
inadequate access to monitoring, poor monitoring quality, and/or
inability to self-monitor
Patients requiring medication interacting with vitamin K antagonists
Patients who have decided against anticoagulation with vitamin K
antagonists despite adequate education
Patients at low risk of gastrointestinal bleeding (dabigatran) and
patients without severe renal dysfunction
Patients who suffered an ischaemic stroke on warfarin with
adequate INR
Patients potentially less suitable for novel anticoagulants in
the early phase after market introduction
Fragile patients, especially those requiring polypharmacotherapy
and with several concomitant diseases may be at increased risk of
accumulating the newer oral anticoagulants or at increased risk
for rare unwanted reactions
Patients with markedly decreased moderately impaired renal
function (MDRD IV–V). The pharmacology suggests that patients
with renal function MDRD stage II– III may be suitable for some of
the factor Xa antagonists, and MDRD II–III patients showed most
benefit on therapy with dabigatran in the RELY study
Patients with history of gastrointestinal bleeding
Patients with poor TTR due to non-adherence may benefit from the
regular reinforcement of therapy by monitoring needed for
vitamin K antagonists therapy
Patients at risk of progressing towards severe renal failure, e.g.
patients with severe heart failure
Patients with coronary artery disease with a high likelihood of
requiring percutaneous revascularization until more data on
combination therapy (vitamin K antagonists plus dual antiplatelet
therapy) are available
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likely that a comprehensive approach to AF management (‘early
and comprehensive therapy of AF’2) can help to improve out-
comes in patients with AF on top of optimal anticoagulation.
This concept of ‘comprehensive rhythm control therapy’ for redu-
cing relevant outcomes in AF patients will be tested in controlled
trials in the near future, including the EAST trial
(ISRCTN04708680, NCT01288352).
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